Regeneron Pharmaceuticals (REGN)

Health Care · $95.2B market cap · SEC CIK 0000872589

Next reports on Jan 28, 2027, after the close, with analysts expecting $26.27 in earnings per share.

52-week range $591.52 to $991.73. 8% below its 52-week high and 55% above its low.

The case for REGN

• Generated $4.1B of free cash flow in FY2025, 28% of revenue.
• 29% of revenue drops through to net profit.
• Holds more cash ($3.1B) than long-term debt ($2.0B).
• Revenue growing 18.6% year over year.
• Reasonably priced for its growth: 19.8× earnings, where 12% a year of growth would justify about 27×.
• Has compounded revenue at 11.0% a year over five years.

The case against

• Weakest against its peers: price/sales of 5.6× is higher than 66% of Health Care companies.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Regeneron Pharmaceuticals's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Regeneron Pharmaceuticals says it does

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others: • competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its…

Risk factors REGN lists in its 10-K

• We are substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent
• The commercial success of our products and product candidates is subject to significant competition
• If we or our collaborators are unable to continue to successfully commercialize our products, our business, prospects, operating results, and financial condition will be materially harmed
• Sales of our marketed products are dependent on the availability and extent of coverage and reimbursement and copay assistance from third-party payors and other third parties
• Implementation of a Medicare Drug Price Negotiation Program
• We rely on our collaborations with Bayer and Sanofi for commercializing some of our marketed products
• If our Antibody Collaboration with Sanofi is terminated, or Sanofi materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to
• develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, may be materially harmed
• Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices
• We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of or significant reduction in sales to these customers would adversely affect our results of operations
• Successful development of our current and future product candidates is uncertain
• Many of our products are intended to be used and, if approved, our product candidates may be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks
• The use of social media platforms could give rise to liability, breaches of data security and privacy laws, or reputational damage
• There are inherent risks related to our increasing use of artificial intelligence-based solutions
• Significant disruptions of information technology systems or breaches of data security could adversely affect our business
• Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, have in the past reduced and could reduce in the future the duration of market exclusivity for our products
• If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our
• business and competitive position will be harmed
• We face risks associated with tariffs and other trade restrictions, which may have a material adverse impact on our results of operations and financial condition
• If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims
• Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties
• Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition
• Changes in laws, regulations, and policies affecting the healthcare industry could adversely affect our business
• Risks associated with our operations outside the United States could adversely affect our business
• We may incur additional tax liabilities related to our operations
• We face risks related to the personal data we collect, process, and share
• Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products
• We have undertaken and may in the future undertake strategic acquisitions, and any difficulties from integrating such acquisitions could adversely affect our business, operating results, and financial condition
• We are dependent on our key personnel and if we cannot recruit or retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed
• Public health outbreaks, epidemics, or pandemics have adversely affected and may in the future adversely affect our business
• Our indebtedness could adversely impact our business
• Changes in foreign currency exchange rates could have a material adverse effect on our operating results
• Our investments are subject to risks and other external factors that may result in losses or affect the liquidity of these investments
• Our stock price is extremely volatile
• Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings
• There can be no assurance that we will continue to repurchase shares of our Common Stock or continue to declare cash dividends
• Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management

Filings

Other Health Care companies